{"title":"24小时尿醛固酮对停服或未停服降压药物患者原发性醛固酮增多症的诊断价值","authors":"Mei You, Xin Li, Huandong Zhao, Zhongping Bai, Yushuang Liu, Qing Zhou, Qiang Li, Ruomei Yang, Hexuan Zhang, Hongbo He, Zhiming Zhu, Zhencheng Yan","doi":"10.1038/s41440-025-02375-w","DOIUrl":null,"url":null,"abstract":"<p><p>Primary aldosteronism (PA) is the most common form of secondary hypertension. However, its diagnosis is complicated by the need to withdraw interfering antihypertensive medications. Traditionally, 24-h urinary aldosterone (Uald) level measurement is employed as part of the oral sodium loading test to diagnose PA. However, the diagnostic efficacy of 24-h Uald for PA under a usual diet and without drug washout remains unclear. This retrospective study enrolled 583 patients with essential hypertension (EH) and 259 patients with PA, as well as an external validation cohort comprising 157 hypertensive patients. Patients with unilateral PA presented higher 24-h Uald levels than those with bilateral PA. Combination antihypertensive therapy reduced 24-h Uald levels in both EH and PA groups. Receiver operating characteristic curve analysis revealed similar areas under the curve for 24-h Uald diagnosing PA between the off-medication group (0.879, 95% CI = 0.834-0.925) and the on-medication group (0.851, 95% CI = 0.817-0.886). The optimal 24-h Uald cut-offs for PA diagnosis were 9.57 μg (sensitivity 79.4%, specificity 88.6%) in the off-medication group and 8.41 μg (sensitivity 75.8%, specificity 79.4%) in the on-medication group, with closely matched thresholds observed between patients receiving renin-increasing medications (8.52 μg) and those on combined renin-increasing and renin-suppressing therapy (8.39 μg). The diagnostic accuracy of 24-h Uald reached 89.2% in the external validation cohort. Our research indicates that the 24-h Uald test is clinically feasible for diagnosing PA without additional sodium supplementation or drug washout. However, the diagnostic threshold for 24-h Uald should be adjusted downward in patients on medications.</p>","PeriodicalId":13029,"journal":{"name":"Hypertension Research","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Diagnostic performance of 24-hour urinary aldosterone for primary aldosteronism in patients with or without discontinuation of antihypertensive medications.\",\"authors\":\"Mei You, Xin Li, Huandong Zhao, Zhongping Bai, Yushuang Liu, Qing Zhou, Qiang Li, Ruomei Yang, Hexuan Zhang, Hongbo He, Zhiming Zhu, Zhencheng Yan\",\"doi\":\"10.1038/s41440-025-02375-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Primary aldosteronism (PA) is the most common form of secondary hypertension. However, its diagnosis is complicated by the need to withdraw interfering antihypertensive medications. Traditionally, 24-h urinary aldosterone (Uald) level measurement is employed as part of the oral sodium loading test to diagnose PA. However, the diagnostic efficacy of 24-h Uald for PA under a usual diet and without drug washout remains unclear. This retrospective study enrolled 583 patients with essential hypertension (EH) and 259 patients with PA, as well as an external validation cohort comprising 157 hypertensive patients. Patients with unilateral PA presented higher 24-h Uald levels than those with bilateral PA. Combination antihypertensive therapy reduced 24-h Uald levels in both EH and PA groups. Receiver operating characteristic curve analysis revealed similar areas under the curve for 24-h Uald diagnosing PA between the off-medication group (0.879, 95% CI = 0.834-0.925) and the on-medication group (0.851, 95% CI = 0.817-0.886). The optimal 24-h Uald cut-offs for PA diagnosis were 9.57 μg (sensitivity 79.4%, specificity 88.6%) in the off-medication group and 8.41 μg (sensitivity 75.8%, specificity 79.4%) in the on-medication group, with closely matched thresholds observed between patients receiving renin-increasing medications (8.52 μg) and those on combined renin-increasing and renin-suppressing therapy (8.39 μg). The diagnostic accuracy of 24-h Uald reached 89.2% in the external validation cohort. Our research indicates that the 24-h Uald test is clinically feasible for diagnosing PA without additional sodium supplementation or drug washout. However, the diagnostic threshold for 24-h Uald should be adjusted downward in patients on medications.</p>\",\"PeriodicalId\":13029,\"journal\":{\"name\":\"Hypertension Research\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.6000,\"publicationDate\":\"2025-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hypertension Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41440-025-02375-w\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hypertension Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41440-025-02375-w","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
摘要
原发性醛固酮增多症(PA)是继发性高血压最常见的形式。然而,由于需要停用干扰性抗高血压药物,其诊断变得复杂。传统上,24小时尿醛固酮(Uald)水平测量被用作口服钠负荷试验的一部分来诊断PA。然而,在正常饮食和没有药物洗脱的情况下,24小时wald对PA的诊断效果尚不清楚。这项回顾性研究纳入了583例原发性高血压(EH)患者和259例PA患者,以及一个包括157例高血压患者的外部验证队列。单侧PA患者24小时wald水平高于双侧PA患者。联合抗高血压治疗降低EH组和PA组24小时wald水平。患者工作特征曲线分析显示,停药组与服药组24 h wald诊断PA曲线下面积相似(0.879,95% CI = 0.834-0.925) (0.851, 95% CI = 0.817-0.886)。停药组诊断PA的最佳24小时Uald临界值为9.57 μg(敏感性79.4%,特异性88.6%),服药组为8.41 μg(敏感性75.8%,特异性79.4%),接受肾素增加药物治疗的患者(8.52 μg)与接受肾素增加和抑制联合治疗的患者(8.39 μg)的阈值密切匹配。在外部验证队列中,24小时wald的诊断准确率达到89.2%。我们的研究表明,24小时wald试验在临床上诊断PA是可行的,无需额外补充钠或药物洗脱。然而,在药物治疗的患者中,24小时wald的诊断阈值应向下调整。
Diagnostic performance of 24-hour urinary aldosterone for primary aldosteronism in patients with or without discontinuation of antihypertensive medications.
Primary aldosteronism (PA) is the most common form of secondary hypertension. However, its diagnosis is complicated by the need to withdraw interfering antihypertensive medications. Traditionally, 24-h urinary aldosterone (Uald) level measurement is employed as part of the oral sodium loading test to diagnose PA. However, the diagnostic efficacy of 24-h Uald for PA under a usual diet and without drug washout remains unclear. This retrospective study enrolled 583 patients with essential hypertension (EH) and 259 patients with PA, as well as an external validation cohort comprising 157 hypertensive patients. Patients with unilateral PA presented higher 24-h Uald levels than those with bilateral PA. Combination antihypertensive therapy reduced 24-h Uald levels in both EH and PA groups. Receiver operating characteristic curve analysis revealed similar areas under the curve for 24-h Uald diagnosing PA between the off-medication group (0.879, 95% CI = 0.834-0.925) and the on-medication group (0.851, 95% CI = 0.817-0.886). The optimal 24-h Uald cut-offs for PA diagnosis were 9.57 μg (sensitivity 79.4%, specificity 88.6%) in the off-medication group and 8.41 μg (sensitivity 75.8%, specificity 79.4%) in the on-medication group, with closely matched thresholds observed between patients receiving renin-increasing medications (8.52 μg) and those on combined renin-increasing and renin-suppressing therapy (8.39 μg). The diagnostic accuracy of 24-h Uald reached 89.2% in the external validation cohort. Our research indicates that the 24-h Uald test is clinically feasible for diagnosing PA without additional sodium supplementation or drug washout. However, the diagnostic threshold for 24-h Uald should be adjusted downward in patients on medications.
期刊介绍:
Hypertension Research is the official publication of the Japanese Society of Hypertension. The journal publishes papers reporting original clinical and experimental research that contribute to the advancement of knowledge in the field of hypertension and related cardiovascular diseases. The journal publishes Review Articles, Articles, Correspondence and Comments.